Patents by Inventor Ralf Jockers

Ralf Jockers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD TO TREAT VIRAL INFECTION INDUCED BY A CORONAVIRUS
    Publication number: 20230172906
    Abstract: The present invention relates the treatment of a viral infection and particularly, the treatment of Covid-19. Melatonin (MLT) and melatoninergic drugs synchronize biological rhythms and sleep patterns, modulate the immune response, modulate the cellular oxidative status and favor cell survival in the lung under stress and inflammatory conditions. In addition to the possible mechanisms of action mentioned above, additional putative mechanism of MLT against SARS-CoV-2 comes from data of the inventors on evaluating the docking of MLT into the solved crystal structure of ACE2 with the viral protein, which revealed a possible interaction of MLT with ACE2 in close proximity to the viral interaction surface. These results suggested that the prophylactic and/or acute treatment with MLT and MLT-derived approved drugs like Ramelteon and Agomelatine, alone or associated with anti-viral or other treatments, could be of therapeutic value.
    Type: Application
    Filed: May 4, 2021
    Publication date: June 8, 2023
    Inventors: Ralf JOCKERS, Erika CECON, Julie DAM
  • Oligonucleotides which inhibit expression of the OB-RGRP protein
    Patent number: 7884084
    Abstract: The present application relates to antisense oligonucleotides which inhibit expression of the OB-RGRP protein and to uses thereof for preventing and/or treating leptin-related pathological conditions. It also relates to a method for detecting compounds which modify the interaction between proteins of the OB-RGRP family and the leptin receptor. This detection may be carried out by measuring the energy transfer between fusion proteins composed of these proteins and of energy-donor and -acceptor proteins.
    Type: Grant
    Filed: February 9, 2004
    Date of Patent: February 8, 2011
    Assignees: Aventis Pharma S.A., Institut National de la Sante Et de la Recherche Medicale, Centre National de la Rechercher Scientifique
    Inventors: Ralf Jockers, Cyril Couturier, Eugen Uhlmann
  • Method for detecting leptin receptor ligands
    Patent number: 7618818
    Abstract: The present invention relates to a method for detecting leptin receptor ligands by measuring the energy transfer between fusion proteins comprising a leptin receptor and an energy donor protein or an energy acceptor acceptor protein proteins. The present invention also relates to fusion proteins for implementing said method.
    Type: Grant
    Filed: April 9, 2007
    Date of Patent: November 17, 2009
    Assignees: Aventis Pharma S.A., Institut de la Sante et de la Recherche Medicale Scientifique, Centre National de la Recherche
    Inventors: Ralf Jockers, Cyril Couturier
  • METHOD FOR DETECTING LEPTIN RECEPTOR LIGANDS
    Publication number: 20070178560
    Abstract: The present application relates to a method for detecting leptin receptor ligands by measuring the energy transfer between fusion proteins composed of leptin receptors and of energy donor and acceptor proteins. It also relates to fusion proteins for implementing this method.
    Type: Application
    Filed: April 9, 2007
    Publication date: August 2, 2007
    Applicants: Aventis Pharma S.A., Institut National De La Sante Et De La Recherche Medicale, CENTRE NATIONAL DE LA RECHERCHER SCIENTIFIQUE
    Inventors: Ralf JOCKERS, Cyril COUTURIER
  • Method for detecting leptin receptor ligands
    Patent number: 7211399
    Abstract: The present invention relates to a method for detecting leptin receptor ligands using resonance energy transfer between fusion proteins comprising a leptin receptor and energy donor protein and a leptin receptor and energy acceptor protein. The present invention also relates to the fusion proteins for implementing said method.
    Type: Grant
    Filed: February 25, 2003
    Date of Patent: May 1, 2007
    Assignees: Aventis Pharma S.A., CNRS, INSERM
    Inventors: Ralf Jockers, Cyril Couturier
  • Oligonucleotides which inhibit expression of the OB-RGRP protein and method for detecting compounds which modify the interaction between proteins of the OB-RGRP family and the leptin receptor
    Publication number: 20050009042
    Abstract: The present application relates to oligonucleotides which inhibit expression of the OB-RGRP protein and to uses thereof for preventing and/or treating leptin-related pathological conditions. It also relates to a method for detecting compounds which modify the interaction between proteins of the OB-RGRP family and the leptin receptor. This detection may be carried out by measuring the energy transfer between fusion proteins composed of these proteins and of energy-donor and -acceptor proteins.
    Type: Application
    Filed: February 9, 2004
    Publication date: January 13, 2005
    Applicants: Aventis Pharma S.A., Institut National De La Sante Et De La Racherche Medicale, Institut National De La Centre National De La Rechercher Scientifique
    Inventors: Ralf Jockers, Cyril Couturier, Eugen Uhlmann
  • Method for detecting leptin receptor ligands
    Publication number: 20040132093
    Abstract: The present application relates to a method for detecting leptin receptor ligands by measuring the energy transfer between fusion proteins composed of leptin receptors and of energy donor and acceptor proteins.
    Type: Application
    Filed: February 25, 2003
    Publication date: July 8, 2004
    Applicant: Aventis Pharma S.A.
    Inventors: Ralf Jockers, Cyril Couturier